Saturday 17 October 2026
Export TRAW’s income statement to Excel — free account
Traws Pharma, Inc.
TRAW Healthcare Biotechnology
Traws Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.8 million, up 1,134.5% from fiscal 2024. In the quarter to June 2026, revenue fell 100.0%, EPS fell 1.78% and free cash flow fell 25.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.37
0.03
−7.50%
Follow TRAW
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | 1.20 | — | — |
P/S ratio |
— | 3.27 | — | — | |
P/FCF ratio |
— | 0.00 | — | — | |
P/Operating CF |
— | (3.37) | — | — | |
P/B ratio |
— | 0.00 | — | — | |
Price to Tangible BV |
— | 0.00 | — | — | |
EV/Sales |
— | 1.92 | — | — | |
EV/EBITDA |
— | 0.00 | — | — | |
EV/Operating CF |
— | (0.30) | — | — | |
EV/FCF |
— | (0.30) | — | — | |
Quick Ratio |
1.07 | 0.68 | 0.36 | 0.87 | |
Current Ratio |
1.22 | 0.72 | 0.43 | 0.93 | |
Net Debt/EBITDA |
1.59 | 0.52 | 0.45 | 1.60 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.16 | 0.00 | 0.00 | |
Operating CF/Net income |
1.32 | 0.61 | 0.45 | 2.87 | |
Capex/Depreciation |
(172.33) | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.21 | 0.24 | 0.30 | 0.21 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
— | (0.35) | — | — | |
Graham Number |
— | 0.00 | — | — | |
Earnings Yield |
— | 83.43% | — | — | |
Free Cash Flow Yield |
— | (195.73%) | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.45) | (0.34) | (0.24) | (0.47) | |
Capex per Share |
(0.29) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.75) | (0.34) | (0.24) | (0.47) | |
Cash per Share |
0.73 | 0.46 | 0.29 | 0.32 | |
Shareholders Equity per Share |
0.52 | (0.08) | (0.50) | 0.11 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.52 | (0.08) | (0.50) | 0.11 | |
Free Cash Flow |
(6.60) | (2.76) | (2.58) | (7.50) | |
Working Capital |
1.74 | (3.17) | (7.54) | (0.71) | |
Capital Expenditures |
(2.58) | 0.00 | — | — | |
Net Current Asset Value |
1.73 | (3.27) | (7.80) | (0.76) | |
EV/EBIT |
— | 0.00 | — | — | |
Capex to Sales |
0.00 | 0.00 | — | — | |
Price to Operating Income |
— | 0.00 | — | — | |
| Other line items | |||||
Average Receivables |
2.06 | 2.78 | 1.67 | 2.39 | |
Average Payables |
5.29 | 6.92 | 7.66 | 5.55 | |
Average Assets |
10.69 | 17.79 | 13.61 | 13.55 | |
Average Common Equity |
1.26 | (16.13) | 0.34 | 4.98 |
Columns are period end dates